Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Lorbrena
| Field | Information |
|---|---|
| Medication Name | Lorbrena |
| Generic Name | Lorlatinib |
| Purpose | Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy. |
| Mechanism of Action | Lorlatinib is a kinase inhibitor that binds to and inhibits ALK, ROS1, TYK1, FER, FAK, TRKA, TRKB, TRKC, and EGFR. |
| Dosage Forms | Oral tablets |
| Available Strengths | 25 mg, 100 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Edema, peripheral neuropathy, cognitive effects, dyspnea, hypercholesterolemia, hypertriglyceridemia, weight gain, arthralgia, fatigue, diarrhea, mood disturbances |
| Serious Side Effects | Hyperlipidemia, central nervous system effects, pneumonitis, atrioventricular (AV) block, hypertension, hyperglycemia, increased lipase and/or amylase |
| Drug Interactions | Strong CYP3A inducers (e.g., rifampin, phenytoin), CYP3A substrates, P-gp substrates |
| Important Notes | Monitor lipid levels regularly. Assess for CNS effects and peripheral neuropathy. Females of reproductive potential should use effective contraception. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). |
| Missed Dose | Take as soon as you remember unless it is less than 4 hours until your next dose. Do not double the dose. |
| Alternatives | Alectinib (Alecensa), Ceritinib (Zykadia), Brigatinib (Alunbrig), Crizotinib (Xalkori) |
Lorbrena Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Alectinib (Alecensa) | ALK and RET inhibitor | Used as first-line treatment in ALK-positive NSCLC. |
| Ceritinib (Zykadia) | ALK inhibitor | Used in patients who have progressed on or are intolerant to crizotinib. |
| Brigatinib (Alunbrig) | ALK and EGFR inhibitor | Effective in patients resistant to crizotinib. |
| Crizotinib (Xalkori) | ALK, ROS1, and MET inhibitor | First-generation ALK inhibitor, often used as initial therapy. |
Lorbrena Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Edema | Hyperlipidemia |
| Peripheral Neuropathy | Central Nervous System Effects (cognitive effects, mood disturbances) |
| Cognitive Effects | Pneumonitis |
| Dyspnea | Atrioventricular (AV) Block |
| Hypercholesterolemia | Hypertension |
| Hypertriglyceridemia | Hyperglycemia |
| Weight Gain | Increased Lipase and/or Amylase |
| Arthralgia | Lung problems: new or worsening cough, shortness of breath, chest pain |
Lorbrena Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| ALK-Positive Metastatic NSCLC | 100 mg | 100 mg once daily | Swallow whole. Can be taken with or without food. |
Lorbrena Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $25,000 |
| Without Insurance (U.S.) | $32,000 |
| From Canada | $24,000 |
